Market overview
The global ocular drug delivery market is worth USD 29.7 bn in 2026 and is forecast to reach USD 53.2 bn by 2036, growing at a 6.0% CAGR. United States is the largest country market and Topical (drops, gels, ointments) is the largest by route segment.
| Scope | Ocular drug delivery: eye drops, intravitreal injections and implants, punctal plugs and delivery devices used to treat eye disease, valued at product sales. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 28.0 bn |
| Value 2026 | USD 29.7 bn |
| Value 2036 | USD 53.2 bn |
| CAGR 2026-2036 | 6.0% |
| Volume 2026 | 1,788 million units |
| Volume 2036 | 2,956 million units |
| Average price 2026 | USD 16.6 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Ocular Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 29.7 bn |
| 2027 | USD 31.5 bn |
| 2028 | USD 33.3 bn |
| 2029 | USD 35.3 bn |
| 2030 | USD 37.5 bn |
| 2031 | USD 39.7 bn |
| 2032 | USD 42.1 bn |
| 2033 | USD 44.6 bn |
| 2034 | USD 47.3 bn |
| 2035 | USD 50.1 bn |
| 2036 | USD 53.2 bn |
Ocular Drug Delivery market segmentation
By route
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Topical (drops, gels, ointments) | 50.0% | 39.2% | USD 14.8 bn | 3.4% |
| Intravitreal injection | 34.0% | 40.7% | USD 10.1 bn | 7.9% |
| Implants and inserts | 9.0% | 13.5% | USD 2.7 bn | 10.4% |
| Periocular and other | 7.0% | 6.6% | USD 2.1 bn | 5.4% |
By disease
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retinal disease (AMD, diabetic eye) | 44.0% | 51.7% | USD 13.1 bn | 7.7% |
| Glaucoma | 16.0% | 13.5% | USD 4.7 bn | 4.2% |
| Dry eye | 20.0% | 17.7% | USD 5.9 bn | 4.7% |
| Infection and inflammation | 12.0% | 9.7% | USD 3.6 bn | 3.7% |
| Other | 8.0% | 7.4% | USD 2.4 bn | 5.2% |
By drug class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Anti-VEGF agents | 34.0% | 34.0% | USD 10.1 bn | 6.0% |
| Corticosteroids | 14.0% | 12.0% | USD 4.2 bn | 4.4% |
| Anti-glaucoma agents | 22.0% | 20.0% | USD 6.5 bn | 5.0% |
| Anti-inflammatory and dry eye | 18.0% | 18.0% | USD 5.3 bn | 6.0% |
| Gene and cell therapy | 12.0% | 16.0% | USD 3.6 bn | 9.1% |
By formulation
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Solutions and suspensions | 44.0% | 38.0% | USD 13.1 bn | 4.5% |
| Implants and inserts | 18.0% | 24.0% | USD 5.3 bn | 9.1% |
| Gels and ointments | 16.0% | 14.0% | USD 4.7 bn | 4.6% |
| Intravitreal injectables | 22.0% | 24.0% | USD 6.5 bn | 6.9% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 36.0% | 34.0% | USD 10.7 bn | 5.4% |
| Specialty eye clinics | 34.0% | 34.0% | USD 10.1 bn | 6.0% |
| Ambulatory surgery centers | 14.0% | 15.0% | USD 4.2 bn | 6.7% |
| Retail pharmacies | 16.0% | 17.0% | USD 4.7 bn | 6.6% |
Top 25 countries for ocular drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 82.5% of 2026 revenue and the 25 countries below together hold 95.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 12.5 bn | 42.0% | USD 22.6 bn | 6.2% |
| 2 | Japan | USD 2.7 bn | 9.0% | USD 4.2 bn | 4.6% |
| 3 | China | USD 2.4 bn | 8.0% | USD 4.3 bn | 6.1% |
| 4 | Germany | USD 1.5 bn | 5.0% | USD 2.4 bn | 5.1% |
| 5 | France | USD 1.2 bn | 4.0% | USD 2.0 bn | 5.2% |
| 6 | United Kingdom | USD 1.2 bn | 4.0% | USD 2.1 bn | 5.7% |
| 7 | Italy | USD 890 mn | 3.0% | USD 1.5 bn | 5.3% |
| 8 | Spain | USD 742 mn | 2.5% | USD 1.3 bn | 5.6% |
| 9 | Canada | USD 742 mn | 2.5% | USD 1.3 bn | 5.6% |
| 10 | Brazil | USD 742 mn | 2.5% | USD 1.5 bn | 7.6% |
| 11 | Australia | USD 718 mn | 2.4% | USD 1.5 bn | 7.4% |
| 12 | Netherlands | USD 591 mn | 2.0% | USD 1.1 bn | 6.5% |
| 13 | South Korea | USD 496 mn | 1.7% | USD 930 mn | 6.5% |
| 14 | Mexico | USD 416 mn | 1.4% | USD 781 mn | 6.5% |
| 15 | India | USD 315 mn | 1.1% | USD 585 mn | 6.4% |
| 16 | Switzerland | USD 243 mn | 0.8% | USD 457 mn | 6.5% |
| 17 | Belgium | USD 214 mn | 0.7% | USD 399 mn | 6.4% |
| 18 | Turkey | USD 166 mn | 0.6% | USD 314 mn | 6.5% |
| 19 | Poland | USD 140 mn | 0.5% | USD 260 mn | 6.4% |
| 20 | Sweden | USD 119 mn | 0.4% | USD 218 mn | 6.3% |
| 21 | Taiwan | USD 95 mn | 0.3% | USD 181 mn | 6.6% |
| 22 | Denmark | USD 77 mn | 0.3% | USD 144 mn | 6.4% |
| 23 | Austria | USD 62 mn | 0.2% | USD 117 mn | 6.5% |
| 24 | Argentina | USD 47 mn | 0.2% | USD 90 mn | 6.6% |
| 25 | Saudi Arabia | USD 39 mn | 0.1% | USD 74 mn | 6.8% |
| Rest of world | USD 1.5 bn | 4.9% | USD 2.8 bn | 6.8% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Regeneron
- Novartis
- Roche
- AbbVie
- Bausch + Lomb
- Alcon
- Bayer
Group 2: Regional and specialist players
- Santen
- Théa
- Ocular Therapeutix
- Senju Pharmaceutical
- Alimera Sciences
- Harrow
- Apellis
- Astellas
- Sun Pharmaceutical
Group 3: Emerging and niche players
- EyePoint Pharmaceuticals
- Glaukos
- Clearside Biomedical
- Oculis
- Eyenovia
- Novaliq
- Nicox
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the ocular drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.0% is calculated from the resulting values.
The market is divided by route, by disease, by drug class, by formulation, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the ocular drug delivery market?
The global ocular drug delivery market is estimated at USD 28.0 bn in 2025 and USD 29.7 bn in 2026.
How fast will the ocular drug delivery market grow?
It is forecast to reach USD 53.2 bn by 2036, a compound annual growth rate of 6.0% from 2026, an increase of USD 23.5 bn.
Which country is the largest market for ocular drug delivery?
United States is the largest market by revenue at USD 12.5 bn in 2026, 42.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, Brazil is growing fastest at 7.6% a year from 2026 to 2036.
Which ocular drug delivery segment is largest?
In the by route split, Topical (drops, gels, ointments) is the largest segment with 50.0% of 2026 revenue.
Who are the leading ocular drug delivery companies?
Global leaders include Regeneron, Novartis, Roche, AbbVie.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Regenerative MedicineUSD 31.6 bn · 13.0% CAGR
- Molecular DiagnosticsUSD 32.4 bn · 8.0% CAGR
- Diabetes CareUSD 32.7 bn · 9.0% CAGR
- Wound CareUSD 26.5 bn · 6.0% CAGR
- Obesity DrugsUSD 33.3 bn · 14.0% CAGR
- Drug Discovery ServicesUSD 26.4 bn · 10.5% CAGR
- Remote Patient MonitoringUSD 25.7 bn · 16.0% CAGR
- Nasal SprayUSD 35.0 bn · 5.5% CAGR